Chimerix Stock

Chimerix Liabilities

Delisted·Apr 17, 2025

The The Liabilities of Chimerix (CMRX) as of Aug 26, 2026 is 24.33 M USD. In the previous year, The Liabilities was 19.75 M USD — a change of 23.22% (higher).

Liabilities

24.33 MUSD

YoY

23.22%

Last updated:

In 2026, Chimerix's total liabilities amounted to 24.33 M USD, a 23.22% difference from the 19.75 M USD total liabilities in the previous year.

The Chimerix Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2017
13.42 M USD
Jan 1, 2018
13.11 M USD
Jan 1, 2019
9.42 M USD
Jan 1, 2020
11.35 M USD
Jan 1, 2021
32.29 M USD
Jan 1, 2022
22.48 M USD
Jan 1, 2023
19.75 M USD
Jan 1, 2024
24.33 M USD
The Chimerix Liabilities history
YEARLiabilitiesYoY
24.33 MUSD+23.22%
19.75 MUSD-12.18%
22.48 MUSD-30.36%
32.29 MUSD+184.55%
11.35 MUSD+20.41%
9.42 MUSD-28.12%
13.11 MUSD-2.31%
13.42 MUSD+27.25%
10.55 MUSD-48.64%
20.53 MUSD+19.09%
17.24 MUSD
Access this data via the Eulerpool API

Chimerix Stock analysis

What does Chimerix do? Chimerix Inc is a biopharmaceutical company focused on the development of antiviral drugs. The company was founded in 2002 and is headquartered in Durham, North Carolina. The history of Chimerix dates back to the research of Dr. George Painter, a renowned scientist in the field of antiviral therapy. He discovered that a certain group of molecules, known as nucleoside analogues, have antiviral properties. The idea was to use these molecules as a starting point for the development of drugs that specifically target viruses. The core idea of Chimerix was to create a new business model that is different from traditional pharmaceutical companies. Instead of focusing on the lengthy and costly development of new compounds, the company wanted to utilize existing molecules and create new drugs through targeted modifications. This approach was not only expected to be faster and cost-effective but also to offer higher chances of success. Chimerix is divided into several business segments. The most important segment is antiviral therapy, where the company focuses on developing drugs against various viruses such as Cytomegalovirus (CMV), Adenovirus, and Herpesvirus. Another business segment of Chimerix is oncology. Here, the company also relies on modifying existing compounds to develop new and effective cancer drugs. One promising molecule currently being developed is Brincidofovir, which not only has antiviral properties but also possesses antitumor properties. In addition to drug development, Chimerix also offers support for clinical trials. The company collaborates with various research institutions and biopharmaceutical companies to test the efficacy and safety of new compounds. The most well-known product of Chimerix is Brincidofovir. This antiviral drug is currently being tested in clinical trials and has the potential to be used against a range of viruses. Its use is particularly promising in patients undergoing immunosuppressive therapy, such as those after a stem cell transplant. Chimerix aims to develop innovative and effective drugs that help patients overcome serious diseases. With its unique business model and close collaboration with the research community, the company has already made promising progress and is an important player in the field of antiviral therapy and oncology. Chimerix is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Chimerix's Liabilities

Chimerix's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Chimerix's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Chimerix's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Chimerix's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Chimerix’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Chimerix stock

The Liabilities of Chimerix is 24.33 M USD in 2026.

The Liabilities of Chimerix changed from 19.75 M USD to 24.33 M USD, representing a 23.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Chimerix since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Chimerix historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Chimerix

All Key Metrics — Chimerix